IRMD IRADIMED CORP

CIK 0001325618 17 ready 8-Ks latest May 1, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 17

Latest filing May 1, 2026, 7:59 PM ET

Top materiality 0.80

Event mix earnings ×10 · other_material ×3 · dividend ×1

Sentiment 13 pos · 0 neg · 4 neu

Latest earnings reported 2026-Q1

Recent 8-K filings for IRMD

Highest-materiality recent filing

Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance

May 1, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).
Declares regular quarterly dividend $0.20/share, payable May 29, 2026 to holders of record May 15, 2026.

Read filing →

May 1, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Iradimed Q1 revenue $22.0M (+13% YoY), EPS $0.45; declares $0.20 dividend; reaffirms FY guidance

Q1 revenue $22.0M (+13% YoY); GAAP diluted EPS $0.45 (+22% YoY); non-GAAP EPS $0.49 (+17% YoY).
February 10, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Iradimed reports record Q4 revenue $22.7M, EPS $0.50; raises dividend to $0.20

Q4 2025 revenue $22.7M (+17% YoY); GAAP diluted EPS $0.50 (+25%), non-GAAP $0.54 (+23%).
December 8, 2025, 6:59 PM ET dividend materiality 0.65 positive item 8.01 item 9.01

iRadimed declares special cash dividend of $0.50 per share

Special dividend of $0.50 per share payable Dec 30, 2025 to holders of record Dec 17, 2025.
November 3, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Iradimed reports record Q3 revenue of $21.2M, up 16% YoY; raises FY2025 guidance

GAAP diluted EPS $0.43, non-GAAP diluted EPS $0.47; net income $5.6M (+10% YoY).
September 2, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 7.01 item 9.01

Iradimed appoints Masimo founder Joe Kiani to board; Anthony Vuoto retires

Anthony Vuoto retired as director effective Aug 27, 2025; no disagreement with the company.
August 1, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Iradimed reports record Q2 revenue of $20.4M (+14% YoY), raises FY2025 guidance

GAAP diluted EPS of $0.45 (up 18% YoY); non-GAAP diluted EPS of $0.49 (up 17% YoY).
June 23, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Iradimed shareholders elect all five director nominees, ratify auditor, approve say-on-pay

Directors elected: Roger Susi (8.85M for), Monty Allen (9.54M), Anthony Vuoto (10.76M), Hilda Scharen-Guivel (10.80M), James Hawkins (8.38M).
May 29, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

iRadimed receives FDA 510(k) clearance for next-gen MRidium 3870 infusion pump

FDA granted 510(k) clearance on May 29, 2025 for the MRidium 3870 IV Infusion Pump System.
May 5, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Iradimed Q1 record revenue $19.5M (+11% YoY); EPS $0.37 GAAP, $0.42 non-GAAP

Record Q1 revenue of $19.5M, up 11% YoY from $17.6M; GAAP diluted EPS $0.37 (+16% YoY).
February 13, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

IRADIMED Q4 revenue $19.4M (+11% YoY); raises quarterly dividend to $0.17/share

Q4 revenue record $19.4M (+11% YoY); GAAP EPS $0.40, non-GAAP EPS $0.44.
January 10, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

iRadimed Q4 2024 revenue range $19.2-$19.4M, record; full-year revenue $73.1-$73.3M, up 11-12% YoY

Q4 2024 revenue ~$19.2M-$19.4M, a record; YoY growth 10-11%, sequential growth 5-6%.
October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

IRADIMED Q3 revenue $18.3M (+11% YoY), raises FY EPS guidance, declares $0.15 dividend

Record Q3 revenue of $18.3M, up 11% YoY from $16.5M; GAAP diluted EPS $0.40, Non-GAAP $0.43.
August 1, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

IRADIMED reports record Q2 revenue $17.9M, GAAP EPS $0.38

Revenue of $17.9M, up 11.2% YoY; operating income $5.6M, up 13.4%.
June 20, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

Iradimed stockholders elect all five director nominees, ratify auditor, approve say-on-pay

All five director nominees elected: Roger Susi (9,119,299 for), Monty Allen (9,709,115), Anthony Vuoto (10,720,742), Hilda Scharen-Guivel (10,741,229), James Hawkins (8,771,444).
June 7, 2024, 7:59 PM ET other material materiality 0.40 positive item 3.01 item 7.01 item 9.01

IRADIMED uplists to Nasdaq Global Market, trading starts June 14, 2024 under IRMD

Nasdaq approved transfer from Capital Market to Global Market, effective June 14, 2024.
June 3, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01

IRADIMED extends headquarters lease by one year to May 2025 in related-party deal

Lease term extended to May 31, 2025, with possible month-to-month holdover through Nov 2025.
May 2, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

IRADIMED reports record Q1 revenue of $17.6M, up 13.7% YoY; EPS $0.32 GAAP, $0.36 non-GAAP

Q1 2024 record revenue $17.6M, +13.7% YoY; operating income $4.7M, +18.5%.

Earnings & guidance

2026-Q1 EPS reported $0.45 filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

13 positive 0 negative 4 neutral

source · IRMD on sec.gov